bullish

Concord Biotech Pre-IPO - Sales Have Been Growing but Watch Out for Its High Concentration Risk

355 Views30 Jan 2023 11:03
Concord Biotech Ltd (658823Z IN) is looking to raise around US$250m in its upcoming India IPO. Concord is an India-based biopharma firm, which develops and manufactures fermentation-based APIs.
SUMMARY
(Sign Up to Access)
Get started on the Smartkarma Research Network with a complimentary Preview Pass to:
  • Unlock all research summaries
  • Follow top, independent analysts
  • Receive personalised alerts and emails
  • Access Briefings, Analytics, and Events

Upgrade anytime to our paid plans for full-length research, real-time analyst discussions, and more.

Join a thriving community of 45,000+ investors, including the top global asset managers managing over $13trn in assets.

or
Already have an account? Sign In Now
Full Insight
(Paid Plans Only, 13-minute read)
Discussions
(Paid Plans Only)
chart-bar
Logo
Top 5%
Clarence Chu
APAC IPOs & Placements
Aequitas Research
EquitiesEquity Capital Markets
x